This case highlights teclistamab as a potential treatment for refractory ITP, suggesting a novel role for B‐cell maturation antigen (BCMA)‐targeted therapies in autoimmune diseases. This evidence concerns the gene TNFRSF17 and autoimmune thrombocytopenic purpura.